Town Hall Cheers CMS Policy Reversal, Urges Vigilance
Participants in Thursday’s Medicare Today tele-town hall applauded the Centers for Medicare and Medicaid Services (CMS) for rethinking a controversial proposal to limit patient access in Medicare Part D – but warned of policy battles to come.
Co-pay Coupon Scare Underscores Access Challenges
UnitedHealthcare patients received welcome news this past week: the insurance provider has retracted its proposal to stop accepting co-pay assistance coupons.
“Stewards” Brief Congress on Curbing Rx Abuse
At a Capitol Hill briefing Wednesday, the Alliance to Prevent the Abuse of Medicines (APAM) offered guidelines for U.S. policymakers who seek to curb prescription drug abuse.
Biosimilars Need Distinguishable Names
Biologics are the fastest growing segment of new medical breakthroughs.
VIEWPOINT: Why Neurologists and Their Patients Must Be Informed When Pharmacists Switch Biologics
Over the past several years, in response to campaigns by the AAN and state neurology societies, a growing number of states have passed laws prohibiting pharmacists from substituting one generic version of an antiepileptic drug (AED) for another without notifying the physician.
Pennsylvania Considers Which Prescriptions to Monitor
Proposed legislation to expand Pennsylvania’s prescription drug monitoring program has the state’s patient advocates worried.
Cancer Care Access Threatened by Payment Disparity
Data suggests the costs of chemotherapy may vary dramatically depending on the care setting.
Want quality care? Keep physicians informed
Imagine seeing a patient who was once dependent upon a cane begin to move about unassisted.
Indiana Gov. signs law on biosimilar substitution
Indiana Governor Mike Pence this week signed Senate Bill 262, a bill on biosimilar drugs that allows substitution if certain conditions are met.
European survey highlights gaps in knowledge of biosimilars
The Alliance for Safe Biologics and EuropaBio recently released results of a survey of 470 European physicians’ views on biosimilar naming.
